Published in Blood Weekly, June 14th, 2001
"Current [APL] therapy includes chemotherapy used in combination with all-trans-retinoic acid (ATRA)," explained R. Foley and colleagues at Henderson General Hospital in Ontario. "Although the differentiating effects of ATRA on promyelocytes have been well established, in vitro studies have shown that less-differentiated APL blasts (CD34+) demonstrate a variable responsiveness to ATRA."
Foley and coworkers found that APL patients with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.